104 related articles for article (PubMed ID: 33554805)
21. Utility of Bone Marrow Biopsy and Aspirate for Staging of Diffuse Large B Cell Lymphoma in the Era of Positron Emission Tomography With 2-Deoxy-2-[Fluorine-18]fluoro-deoxyglucose Integrated With Computed Tomography.
Vishnu P; Wingerson A; Lee M; Mandelson MT; Aboulafia DM
Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):631-636. PubMed ID: 28684378
[TBL] [Abstract][Full Text] [Related]
22. Investigation of expressions of PDK1, PLK1 and c-Myc in diffuse large B-cell lymphoma.
Feng Y; Lin J; Liu Y; Tang Y; Zhou Y; Zhong M
Int J Exp Pathol; 2019 Feb; 100(1):32-40. PubMed ID: 30912195
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathological Features, Treatment, and Prognosis in Primary Diffuse Large B Cell Lymphoma of the Breast: A Retrospective Study of 46 Patients.
Luo H; Yi P; Wang W; Li K; Meng L; Li J; Zeng W; Tang M
Med Sci Monit; 2019 Nov; 25():8671-8682. PubMed ID: 31734687
[TBL] [Abstract][Full Text] [Related]
24. [Clinical characteristics and prognosis of diffuse large B-cell lymphoma].
Yang BY; Yong WB; Zhu J; Zheng W; Zhang YT; Wang XP; Meng SN
Zhonghua Zhong Liu Za Zhi; 2005 Mar; 27(3):174-6. PubMed ID: 15946571
[TBL] [Abstract][Full Text] [Related]
25. CD43 expression in diffuse large B-cell lymphoma, not otherwise specified: CD43 is a marker of adverse prognosis.
Ma XB; Zheng Y; Yuan HP; Jiang J; Wang YP
Hum Pathol; 2015 Apr; 46(4):593-9. PubMed ID: 25682152
[TBL] [Abstract][Full Text] [Related]
26. [Analysis of survival and treatment outcome of young patients with high-risk diffuse large B cell lymphoma].
Yang P; Jing HM; Zhao W; Hu K; Dong F; Li QH; Wan W; Tian L; Wang JJ; Ke XY
Zhonghua Yi Xue Za Zhi; 2017 Aug; 97(32):2485-2490. PubMed ID: 28835053
[No Abstract] [Full Text] [Related]
27. FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.
Wong KK; Gascoyne DM; Soilleux EJ; Lyne L; Spearman H; Roncador G; Pedersen LM; Møller MB; Green TM; Banham AH
Oncotarget; 2016 Aug; 7(33):52940-52956. PubMed ID: 27224915
[TBL] [Abstract][Full Text] [Related]
28. Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP.
Wang Y; Li YJ; Jiang WQ; Rao HL; Huang JJ; Xia Y; Bi X; Sun P; Huang HQ; Lin TY; Guan ZZ; Li ZM
Ann Hematol; 2015 Nov; 94(11):1865-73. PubMed ID: 26327569
[TBL] [Abstract][Full Text] [Related]
29. Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma.
Xia B; Zhang L; Guo SQ; Li XW; Qu FL; Zhao HF; Zhang LY; Sun BC; You J; Zhang YZ
World J Gastroenterol; 2015 Feb; 21(8):2433-42. PubMed ID: 25741152
[TBL] [Abstract][Full Text] [Related]
30. Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab.
Rasheed AA; Samad A; Raheem A; Hirani SI; Shabbir- Moosajee M
Asian Pac J Cancer Prev; 2018 Feb; 19(2):331-335. PubMed ID: 29479962
[TBL] [Abstract][Full Text] [Related]
31. Expression of PD-1 (CD279) and FoxP3 in diffuse large B-cell lymphoma.
Ahearne MJ; Bhuller K; Hew R; Ibrahim H; Naresh K; Wagner SD
Virchows Arch; 2014 Sep; 465(3):351-8. PubMed ID: 25011996
[TBL] [Abstract][Full Text] [Related]
32. Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?
Mondello P; Steiner N; Willenbacher W; Ferrero S; Ghione P; Marabese A; Pitini V; Cuzzocrea S; Mian M
Oncologist; 2016 Sep; 21(9):1107-12. PubMed ID: 27382029
[TBL] [Abstract][Full Text] [Related]
33. [Effect of Different Protein Expression and Clinical Features on the Prognosis of Patients with Diffuse Large B-Cell Lymphoma].
Cheng FF; Chen JF; Yang LH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Oct; 27(5):1490-1496. PubMed ID: 31607303
[TBL] [Abstract][Full Text] [Related]
34. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
[TBL] [Abstract][Full Text] [Related]
35. [Expression and Significance of LncRNA RP11-513G11.1 in Peripheral Blood of Patients with Diffuse Large B-Cell Lymphoma].
Tang JL; Li XM; Zhang L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Oct; 27(5):1515-1521. PubMed ID: 31607306
[TBL] [Abstract][Full Text] [Related]
36. [Clinicopathological characteristics and prognostic analysis of primary intestinal diffuse large B-cell lymphoma].
Huang Y; Zhou S; He X; Gui L; Yang J; Liu P; Qin Y; Zhang C; Xing P; Yang S; Wang L; Zhou L; Dong M; Sun Y; Shi Y
Zhonghua Yi Xue Za Zhi; 2015 Dec; 95(48):3895-8. PubMed ID: 27122208
[TBL] [Abstract][Full Text] [Related]
37. [Expression and prognostic significance of microenvironment related prognostic factors in patients with classical Hodgkin's lymphoma].
Wang TT; Li SX; Xia B; Zhao HF; Xu W; Yang HL; Wang XF; Yu Y; Sun BC; Zhang YZ
Zhonghua Yi Xue Za Zhi; 2017 May; 97(18):1400-1405. PubMed ID: 28535626
[No Abstract] [Full Text] [Related]
38. [Impact of PRDM1 gene inactivation on C-MYC regulation in diffuse large B-cell lymphoma].
Zhang XY; Ma ZP; Cui WL; Pang XL; Chen R; Wang L; Zhang W; Li XX
Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):25-31. PubMed ID: 29325247
[No Abstract] [Full Text] [Related]
39. [Prognostic analysis of 525 Chinese patients with diffuse large B cell lymphoma].
Fu ZY; Zhu J; Song YQ; Liu WP; Ji XQ; Zhan SY
Beijing Da Xue Xue Bao Yi Xue Ban; 2014 Jun; 46(3):405-11. PubMed ID: 24943019
[TBL] [Abstract][Full Text] [Related]
40. [Clinical Significance of TF and VEGF Expressions on Peripheral CD14 Positive Monocytes in Patients with Diffuse Large B Cell Lymphoma].
Jiang YJ; Zhu GH; He Y; Chai XX; Yang XY; Meng FJ; Zhuang WC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):67-73. PubMed ID: 30738449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
